Open AccessClinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy
Author(s) -
Ye Won Jeon,
Seung Taek Lim,
Hongki Gwak,
Seon-Young Park,
Jongbeom Shin,
Hye Sug Han,
Young Jin Suh
Publication year - 2021
Publication title -
annals of surgical treatment and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.559
H-Index - 25
eISSN - 2288-6796
pISSN - 2288-6575
DOI - 10.4174/astr.2021.100.2.59
Subject(s) - pegfilgrastim , medicine , docetaxel , febrile neutropenia , neutropenia , cyclophosphamide , chemotherapy , granulocyte colony stimulating factor , incidence (geometry) , breast cancer , surgery , oncology , cancer , physics , optics
Treatment with 4 cycles of docetaxel and cyclophosphamide (TC) in the adjuvant setting is associated with better outcomes than treatment with doxorubicin and cyclophosphamide (AC). However, Western guidelines have indicated that TC confers a high risk (>20%) of febrile neutropenia (FN), while AC confers an intermediate risk (10%-20%) of FN. Threrefore, we evaluated the incidence of FN and the clinical utilization of pegfilgrastim prophylaxis after adjuvant TC chemotherapy.